Thursday, July 20, 2006

Gilead To Acquire Corus Pharma For $365M

Gilead Sciences is acquiring Seattle-based Corus Pharma in a deal worth $365M, the firm said yesterday. Gilead said that it has agreed to exercise its option to acquire the firm, which is commercialization products for treating respiratory and infection diseases. Corus is backed by Bear Stearns Health Innoventures, Burrill & Company, JPMorgan Partners (now known as Panorama Capital), Novo A/S, Orbimed Advisors and others.